Clinical trials: Anti-PD-1
Melanoma
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
Despite being standard of care, there are still many medical requirements related to immune checkpoint blocker based therapies such as identify patients susceptible to respond with the less adverse events, evaluate the clinical…
- Trial name
- PHENOMENAL (NCT06154668)
- Where
- France
- Volunteers
- 707 people
- Sponsor
- University Hospital, Grenoble
Melanoma
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
The primary objective of this single arm phase 2 trial is to assess the response rate [complete response (CR) + partial response (PR)] of sequential therapy of pembrolizumab followed by HD IL-2 in subjects with stage IV malignant…
- Trial name
- NCT03476174
- Testing
- Pembrolizumab, Interleukin-2
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ralph Hauke
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Extranodal NK/T-cell Lymphoma, Nasal Type
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
For patients with NK/T-cell lymphoma, plasma EBV-DNA has been found to be a prognostic factor, and those with positive plasma EBV-DNA at the end of treatments are more likely to suffer from disease relapse.
- Trial name
- NCT04338282
- Testing
- toripalimab
- Volunteers
- 20 people
- Sponsor
- Beijing Tongren Hospital
Advanced Gastric Adenocarcinoma
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).
- Trial name
- NCT04209686
- Testing
- Paclitaxel, Olaparib, Pembrolizumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Squamous Cell Carcinoma
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma
The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on cognitive function in patients with resectable head and neck squamous cell…
- Trial name
- NCT06576180
- Testing
- Carboplatin（ neoadjuvant）, Paclitaxel （neoadjuvant）, Anti-PD-1 Drugs
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasal Type Extranodal NK/T-Cell Lymphoma
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
This open-label, single arm study will evaluate the efficacy and safety of anti-PD-1 antibody in combination with pegaspargase in treatment of newly diagnosed advanced stage NK/T-cell lymphoma.
- Trial name
- NCT04096690
- Testing
- Pegaspargase, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Ruijin Hospital
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
This randomized pilot early phase I trial studies the side effects and how well nivolumab alone works compared to nivolumab with bevacizumab or ipilimumab before surgery in treating patients with kidney cancer, also referred to…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT02210117
- Testing
- Bevacizumab, Biopsy, Ipilimumab
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, with more than 700,000 new cases in the world every year.
- Trial name
- CISLD-8 (NCT04418401)
- Testing
- Donafenib and anti-PD-1 antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine+Camrelizumab in patients with Hodgkin…
- Trial name
- NCT04514081
- Testing
- Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Melanoma
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
Phase II study evaluating the benefit of the combination of anti-PD1 (pembrolizumab) and anti-CTLA4 (ipilimumab) antibodies in advanced melanoma.
- Trial name
- NCT02743819
- Testing
- Pembrolizumab, Ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
Melanoma, Non Small Cell Lung Cancer
PDR001 + Panobinostat for Melanoma and NSCLC
The purpose of this research study is to find the dose of the study drug PDR001 that, when given in combination with the drug Panobinostat, results in the best outcomes for metastatic melanoma and non-small cell lung cancer…
- Trial name
- NCT03982134
- Testing
- PDR001, Panobinostat
- Sponsor
- Muhammad Furqan
Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well…
- Trial name
- NCT07111520
- Testing
- BNT326, Pumitamig
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 880 people
- Sponsor
- BioNTech SE
Non-small Cell Lung Cancer
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of…
- Trial name
- NCT03515629
- Testing
- REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 5 people
- Sponsor
- Regeneron Pharmaceuticals
Neuroendocrine Tumors
Study of JS001 in Patients With Advanced Neuroendocrine Tumors
This is a multi-center, open-label, phase Ib study evaluating safety and efficacy of the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with neuroendocrine tumors who have failed in previous systemic treatment.
- Trial name
- NCT03167853
- Testing
- humanized anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Colorectal Cancer, Endometrium Cancer
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
Single Center, open label, Phase I-II trial designed to test the safety and efficacy of the combination of Ataluren and Pembrolizumab for the treatment of metastatic mismatch repair deficient and proficient colorectal…
- Trial name
- ATAPEMBRO (NCT04014530)
- Testing
- Ataluren + Pembrolizumab
- Where
- Netherlands
- Volunteers
- 47 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Chronic Hepatitis B Infection, Chronic Hepatitis D Infection
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Primary objective: To evaluate the safety and tolerability of sequential administration of P1101 and anti-PD1 in patient with chronic hepatitis B or D infection Secondary objectives: 1.
- Trial name
- NCT04638439
- Testing
- P1101 + Nivolumab + Entecavir
- Where
- 5 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- PharmaEssentia
Gastric Cancer
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
This is a randomized, controlled, multicenter phase Ⅲ study to evaluate the therapeutic efficacy of modified XELOX plus sintilimab versus standard XELOX plus sintilimab in subjects with advanced HER2-negative gastric or…
- Trial name
- NCT05918094
- Testing
- Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab
- Where
- 10 sites in China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Metastatic Melanoma
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
This open-label phase II trial studies how well olaparib in combination with pembrolizumab works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
- Trial name
- NCT04633902
- Testing
- Olaparib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- California Pacific Medical Center Research Institute
Soft Tissue Sarcoma, Bone Sarcoma
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
- Trial name
- NCT02301039
- Testing
- Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 144 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.